Tag Archives: MaRS

LSN Launches RESI on MaRS Innovation Challenge with an All New Application Portal – LSN Sourcing & Ranking Expert System

25 Jan

By Samuel Rubin, Business Development Manager, LSN

After receiving some excellent feedback from past applicants, the RESI Innovation Challenge Review Team has re-tooled the online application to create a standardized and efficient Sourcing & Ranking Expert System. For years LSN has been evaluating technologies for government organizations, large pharma, and other groups using this system to vet biotech, medtech, diagnostics, and healthcare IT companies based on their science and “invest-ability”.

LSN believes the RESI Innovation Challenge application process will now be more logical and easier to navigate, streamlining the process from beginning to end. The application has now launched online. The deadline to apply for RESI on MaRS is Friday March 2nd. We look forward to reviewing all of your impressive applications!

RESI on MaRS 2017 Dynamic Statistics

18 Jan

By Chris Cummings, Senior Marketing Manager, LSN

In April 2017, RESI brought over 250 qualified life science investors to the Toronto ecosystem. The investors came from all corners of the globe; large strategic partners flew in from China to join local family offices just down the street from MaRS Discovery District. Over 900 meetings occurred over the course of the day. Taking a closer look at exactly where investors came from and who they met with confirms the global cross-pollination of early stage life science RESI fosters.

RESI, for that day, was able to expand the pool of capital in Toronto beyond Canada’s borders. About 50% of the investors who attended the event were from the United States, Europe, or Asia.

Investment firm types were far from homogenous as well. No single category of investor dominated the event, creating a platform where every fundraising company can find the capital that most accurately suits their needs.

Investors came to RESI on MaRS primarily to meet with new interesting technology. Over 80% of investor meetings were with fundraising companies.

RESI also offers a platform for fundraising companies to collaborate with relevant service providers, non-profits, and even other fundraising companies.

This data goes to show that RESI on MaRS truly offers an unparalleled platform for players in the early stage life science game to find partners from across the world, driving innovation forward and, ultimately, putting much needed treatments in the hands of patients.

Redefining Early Stage Investments (RESI) Conference on MaRS Report

13 Apr

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

RESI’s first MaRS landing was in Summer 2016, and the success of the event revealed a tremendous appetite for an early stage life science investment venue in Toronto.

For 2017, RESI on MaRS built on its initial success to become the centerpiece of the new Toronto Health Innovation Week – a sequence of summits, conferences and receptions that gathered together the most vital players in Toronto’s healthcare ecosystem.  As RESI continues its cycle of events throughout North America, we look forward to working with local bio-med innovation hubs in every RESI city to showcase their innovations and technology resources.

Last week’s RESI on MaRS grew significantly over our 2016 event. Delegates came to RESI from 12 countries. There was a 25% increase in investor attendance. In all, more than 600 attendees came to RESI on MaRS to pitch their ideas or to find new investment opportunities.

More bandwidth was added for RESI Partnering meetings – RESI attendees exchanged over 3000 meeting requests, and 1000 scheduled one-on-one meetings took place. Outside of RESI Partnering, the halls of MaRS Discovery District buzzed with ad-hoc meetings and networking encounters.

30 companies competed in the RESI Innovation Challenge. The victor, Steadiwear, was a MaRS portfolio company.

Partnering Forum

RESI on MaRS also featured three full tracks of content. In RESI’s 16 investor panels, attendees heard from a wide variety of early stage investors and strategic players who are looking to Toronto for new technology opportunities. Some panels focused on a particular funding source such as Family Offices, Public Private Partnerships and Corporate Venture Capital. Others looked at the diversity of the investment landscape in a specific technology vertical, such as Diagnostics or Medical Devices. Meanwhile, the Tales From The Road panel – seasoned life science CEOs who have recent experience of raising capital – spoke about how they’d met the challenge of attracting global investors to back their Canadian startups.

Incubator Accelerator New Models Panel (Ying Tam, Managing Director Health, MaRS Discovery District | Frédéric Lemaitre Auger, Senior Director, Investments, Accel-Rx – Canada’s Health Science Accelerator | Rebecca Yu, Head of JLABS @ Toronto, Johnson & Johnson Innovation | Randy Yatscoff, Executive Vice President, Business Development, TEC Edmonton | Kristi Ebong, Head Strategy Business Development, Cedars-Sinai Health System)

The RESI Asia-North America Partnering Track was added to the event, drawing high level decision makers from healthcare investment firms and major healthcare corporations from China, Japan, Korea, and Taiwan. These investors defined their interest in investing in healthcare startups in Canada and the US, and explained how to work with a partner in Asia to reach a new marketplace and grow your company.

Asia Pharma Partners Panel (Hiroshi Kawai, Vice President, Mitsubishi Tanabe Holdings America | Tianle Redanz, Director of Business Development, Simcere of America | Weiyong Sun, Senior Director External Scientific Affairs, Daiichi Sankyo | Richard Soll, Senior Vice President, Research Service Division (RSD), WuXi AppTec)

It’s clear that Toronto has a strong ecosystem for generating new healthcare technologies and launching new companies, and RESI on MaRS has served as a catalyst to join those new technologies with relevant, active investors who see the advantages of investing in Canada. By building these new bridges between technology and capital, RESI on MaRS will move science forward in Toronto.

RESI’s next stop will be in San Diego on Monday June 19th – the first RESI event to take place concurrent with the BIO International Convention. If you’d like to join LSN for a day of investor meetings, new panel content and high level networking, you can register now.

RESI on MaRS Innovation Challenge – Winners Announced

6 Apr

By Nono Hu, Director of Marketing, LSN

On April 4, more than 600 entrepreneurs and investors entered the exhibition hall at MaRS Discovery District in Toronto. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. Here, LSN would like to present the top 3 winners who attracted the greatest amount of “RESI Cash”.

First Place: Steadiwear

Steadiwear inc.‘s mission is to restore independence and quality of life to all tremor sufferers worldwide. We have developed the Steadiglove, a smart glove that responsively stabilizes hand tremors in Essential Tremor and Parkinson’s disease using novel vibration damping technology. This allows users to go about all daily activities such as eating and getting dressed with significantly less frustration.

Michael Quigley, VP of Market Research, Life Science Nation | Mark Elias, CEO, Co-founder, Steadiwear | Emile Maamary, CFO, Co-founder | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation

Second Place: BlueLight

BlueLight is a healthcare technology company specializing in the measurement of light energy. Our data-driven technologies, sold worldwide, target a quality gap in the multi billion-dollar dental composite market.

Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation | Michael Quigley, VP of Market Research, Life Science Nation | JP Furey, CEO, BlueLight | Peter MacLareN, Director of Customer Relations, BlueLight

Third Place: Cyclica

Cyclica Inc. has developed, validated, and patented a structure-based proteome-wide screening platform, Ligand Express™, that currently features PROBEx (proteome-screening), SWITCHx (ligand effect prediction) and DIVEx (systems biology & drug-protein interactomes). Ligand Express™ is unique in that it is a drug-centric platform. For a small molecule ligand, Ligand Express™ automatically generates an intelligent list of ligand-protein interactions by searching through a large proprietary database of all available structurally characterized proteins. The platform provides a panoramic view of a small molecule ligand to better understand on- and off-target interactions, and is valuable in finding novel desirable or undesirable targets. By gaining insights into a ligand’s polypharmacology, Cyclica’s clients can identify unknown targets, prioritize lead candidates, elucidate adverse effects, and understand repurposing opportunities.

Michael Quigley, VP of Market Research, Life Science Nation | Naheed Kurji, President and CEO, Cyclica | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation

Thank you to all who competed in the RESI on MaRS Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

Redefining Early Stage Investments Conference Series – RESI on MaRS 2017 Program Guide

23 Mar

By Nono Hu, Director of Marketing, LSN

With RESI on MaRS coming up in 10 days, the LSN team is getting ready to head to Canada’s hub of healthcare innovation, Toronto!  RESI on MaRS will bring more than 250 investors under one roof, providing you with one-of-a-kind networking and partnering experience.

LSN is proud to present the RESI on MaRS Program Guide. If you’re planning your day at RESI on April 4, 2017 to see full lists of the investor panel speakers, RESI Innovation Challenge finalists and service providers you could meet, look no further!

Healthcare IT Investors Share Their Strategies at RESI on MaRS

16 Mar

By Cole Bunn, Senior Research Analyst, LSN


Healthcare IT entrepreneurs, as opposed to biotech/medtech entrepreneurs, enjoy some favorable realities when it comes to successfully launching and sustaining a new venture. However, even though software and healthcare IT companies require far less capital than a biopharmaceutical product or medical device to get up and running, investors tend to place an emphasis on market penetration and traction, often the rate limiting step for these startups. A key to overcoming this hurdle is healthy ecosystem with innovative institutions willing to put programs in place to help new digital health technologies enter the marketplace and refine their product.

Canada is embracing digital health and the impact it can have on the public, patients and the healthcare system at large. Toronto, as the epicenter of Canadian healthcare and innovation, is naturally working to catalyze venture creation in healthcare IT and will host the RESI conference and a panel of venture investors active in the space.

The session will feature the following investors:

By registering for RESI on MaRS, you’ll be able to listen to the Healthcare IT panel live, interact with the investors and experience numerous opportunities to expand your network.

30 Leading Life Science Startups Compete in Innovation Challenge at The Redefining Early Stage Investments (RESI) Conference at MaRS

9 Mar

By Michael Quigley, VP of Market Research, LSN


As RESI gears up for its second landing on MaRs in Toronto this April 4th we are proud to announce our latest batch of life science/health tech companies that will be participating in the RESI Innovation Challenge.

30 companies from across North America, hand selected by LSN’s scientific and commercial review team, will compete directly on merits of innovation and commercial viability.  Past RESI events have seen as many as 50% of innovation challenge contestants go on to receive funding or significant partnerships within a year from the competition.

From companies helping to detect oncoming seizures to those developing cost effective ways of growing blood stem cells, this diverse class of competitors is sure to impress. Come check them our yourself in the Exhibition Hall at RESI on MaRs on April 4th!

Medical Device
Healthcare IT
%d bloggers like this: